Compare H2O America (HTO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Revvity Inc — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7× H2O America's market cap, and H2O America pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Revvity Inc for 12 Days on average.
| HTO | RVTY | |
|---|---|---|
Market Cap | $2.43B | $16.98B |
Volume | 593,883 | 1,456,900 |
Sector | Utilities | Health |
52-Week High | $65.43 | $157.36 |
52-Week Low | $44.44 | $82.26 |
Typical Hold Time | 40 Days | 12 Days |
Enterprise Value | $4.22B | $19.30B |
Dividend Yield | 3.03% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.07, up 0.16% with a bearish technical signal despite bullish oscillators. The company shows solid fundamentals with 12.91% net income margin and recent earnings beats in Q1 and Q2 2026. Recent acquisitions in Texas signal growth ambitions, though cash flow trends show heavy investing activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
The stock offers potential upside to analyst targets but faces execution risks from recent acquisitions and dilution concerns. Strong institutional interest from BlackRock and others supports the growth story, though technical weakness and high investing cash outflows warrant monitoring. The Dividend King status provides income stability amid expansion efforts.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
